Albania

Albania

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.64 (0.57 - 0.71) 2019 Modelled IHME
0.68 (0.60 - 0.76) 2018 Modelled IHME
0.7 (0.61 - 0.79) 2017 Modelled IHME
0.69 (0.60 - 0.78) 2016 Modelled IHME
0.68 (0.59 - 0.78) 2015 Modelled IHME
0.69 (0.60 - 0.78) 2014 Modelled IHME
0.7 (0.61 - 0.79) 2013 Modelled IHME
0.71 (0.62 - 0.81) 2012 Modelled IHME
0.72 (0.63 - 0.82) 2011 Modelled IHME
0.74 (0.64 - 0.84) 2010 Modelled IHME
0.75 (0.65 - 0.85) 2009 Modelled IHME
0.76 (0.66 - 0.86) 2008 Modelled IHME
0.77 (0.67 - 0.87) 2007 Modelled IHME
0.78 (0.68 - 0.88) 2006 Modelled IHME
0.8 (0.69 - 0.90) 2005 Modelled IHME
0.81 (0.70 - 0.92) 2004 Modelled IHME
0.83 (0.72 - 0.94) 2003 Modelled IHME
0.85 (0.74 - 0.96) 2002 Modelled IHME
0.86 (0.75 - 0.98) 2001 Modelled IHME
0.88 (0.76 - 1.02) 2000 Modelled IHME
0.91 (0.78 - 1.03) 1999 Modelled IHME
0.93 (0.79 - 1.06) 1998 Modelled IHME
0.96 (0.80 - 1.10) 1997 Modelled IHME
0.98 (0.81 - 1.13) 1996 Modelled IHME
0.98 (0.81 - 1.15) 1995 Modelled IHME
0.98 (0.81 - 1.15) 1994 Modelled IHME
0.99 (0.81 - 1.15) 1993 Modelled IHME
0.99 (0.81 - 1.15) 1992 Modelled IHME
0.99 (0.80 - 1.16) 1991 Modelled IHME
0.98 (0.79 - 1.17) 1990 Modelled IHME
9.42 (7.77 - 11.37) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.03 (0.02 - 0.04) 2019 Modelled IHME
0.03 (0.02 - 0.04) 2018 Modelled IHME
0.03 (0.02 - 0.04) 2017 Modelled IHME
0.03 (0.02 - 0.04) 2016 Modelled IHME
0.03 (0.02 - 0.04) 2015 Modelled IHME
0.03 (0.02 - 0.04) 2014 Modelled IHME
0.03 (0.02 - 0.04) 2013 Modelled IHME
0.03 (0.02 - 0.04) 2012 Modelled IHME
0.03 (0.02 - 0.04) 2011 Modelled IHME
0.03 (0.02 - 0.04) 2010 Modelled IHME
0.03 (0.02 - 0.04) 2009 Modelled IHME
0.03 (0.02 - 0.04) 2008 Modelled IHME
0.03 (0.02 - 0.04) 2007 Modelled IHME
0.03 (0.02 - 0.05) 2006 Modelled IHME
0.03 (0.02 - 0.05) 2005 Modelled IHME
0.04 (0.03 - 0.05) 2004 Modelled IHME
0.04 (0.03 - 0.05) 2003 Modelled IHME
0.04 (0.03 - 0.06) 2002 Modelled IHME
0.05 (0.03 - 0.06) 2001 Modelled IHME
0.05 (0.04 - 0.06) 2000 Modelled IHME
0.05 (0.04 - 0.07) 1999 Modelled IHME
0.06 (0.04 - 0.07) 1998 Modelled IHME
0.06 (0.04 - 0.08) 1997 Modelled IHME
0.06 (0.05 - 0.08) 1996 Modelled IHME
0.07 (0.05 - 0.09) 1995 Modelled IHME
0.1 (0.07 - 0.14) 1994 Modelled IHME
0.18 (0.12 - 0.23) 1993 Modelled IHME
0.28 (0.20 - 0.38) 1992 Modelled IHME
0.41 (0.28 - 0.55) 1991 Modelled IHME
0.55 (0.37 - 0.73) 1990 Modelled IHME
1.29 (0.83 - 1.91) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
23 (16 - 32) 2019 Modelled IHME
23 (16 - 32) 2018 Modelled IHME
23 (16 - 32) 2017 Modelled IHME
23 (16 - 32) 2016 Modelled IHME
23 (17 - 32) 2015 Modelled IHME
24 (17 - 32) 2014 Modelled IHME
24 (17 - 32) 2013 Modelled IHME
24 (17 - 32) 2012 Modelled IHME
24 (17 - 32) 2011 Modelled IHME
24 (17 - 33) 2010 Modelled IHME
24 (17 - 33) 2009 Modelled IHME
24 (17 - 33) 2008 Modelled IHME
24 (17 - 33) 2007 Modelled IHME
24 (17 - 33) 2006 Modelled IHME
25 (18 - 33) 2005 Modelled IHME
25 (18 - 34) 2004 Modelled IHME
25 (18 - 34) 2003 Modelled IHME
26 (19 - 35) 2002 Modelled IHME
27 (20 - 37) 2001 Modelled IHME
28 (20 - 37) 2000 Modelled IHME
28 (21 - 38) 1999 Modelled IHME
29 (21 - 38) 1998 Modelled IHME
29 (21 - 38) 1997 Modelled IHME
29 (21 - 38) 1996 Modelled IHME
29 (22 - 39) 1995 Modelled IHME
30 (22 - 39) 1994 Modelled IHME
30 (22 - 39) 1993 Modelled IHME
30 (23 - 39) 1992 Modelled IHME
30 (23 - 40) 1991 Modelled IHME
30 (22 - 39) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
99 2018 Survey/reported WHO/UNICEF
99 2017 Survey/reported WHO/UNICEF
99 2016 Survey/reported WHO/UNICEF
99 2015 Survey/reported WHO/UNICEF
99 2014 Survey/reported WHO/UNICEF
99 2013 Survey/reported WHO/UNICEF
97 2012 Survey/reported WHO/UNICEF
97 2011 Survey/reported WHO/UNICEF
99 2010 Survey/reported WHO/UNICEF
98 2009 Survey/reported WHO/UNICEF
98 2008 Survey/reported WHO/UNICEF
98 2007 Survey/reported WHO/UNICEF
99 2006 Survey/reported WHO/UNICEF
99 2005 Survey/reported WHO/UNICEF
99 2004 Survey/reported WHO/UNICEF
98 2003 Survey/reported WHO/UNICEF
99 2002 Survey/reported WHO/UNICEF
98 2001 Survey/reported WHO/UNICEF
98 2000 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
99 2018 Survey/reported WHO/UNICEF
99 2017 Survey/reported WHO/UNICEF
98 2016 Survey/reported WHO/UNICEF
99 2015 Survey/reported WHO/UNICEF
98 2014 Survey/reported WHO/UNICEF
99 2013 Survey/reported WHO/UNICEF
99 2012 Survey/reported WHO/UNICEF
99 2011 Survey/reported WHO/UNICEF
99 2010 Survey/reported WHO/UNICEF
98 2009 Survey/reported WHO/UNICEF
99 2008 Survey/reported WHO/UNICEF
98 2007 Survey/reported WHO/UNICEF
98 2006 Survey/reported WHO/UNICEF
98 2005 Survey/reported WHO/UNICEF
99 2004 Survey/reported WHO/UNICEF
97 2003 Survey/reported WHO/UNICEF
96 2002 Survey/reported WHO/UNICEF
96 2001 Survey/reported WHO/UNICEF
96 2000 Survey/reported WHO/UNICEF
96 1999 Survey/reported WHO/UNICEF
94 1998 Survey/reported WHO/UNICEF
97 1997 Survey/reported WHO/UNICEF
96 1996 Survey/reported WHO/UNICEF
88 1995 Survey/reported WHO/UNICEF
99 1994 Survey/reported WHO/UNICEF
Showing out of
Show more
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes
Year of birth dose introduction
2000
Eligible for HBV generic medicines
HBV National Action Plan
HBV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.01 (0.82 - 1.24) 2019 Modelled IHME
1.01 (0.82 - 1.24) 2018 Modelled IHME
1 (0.81 - 1.23) 2017 Modelled IHME
0.99 (0.80 - 1.22) 2016 Modelled IHME
0.98 (0.79 - 1.21) 2015 Modelled IHME
0.97 (0.79 - 1.21) 2014 Modelled IHME
0.97 (0.79 - 1.20) 2013 Modelled IHME
0.97 (0.78 - 1.20) 2012 Modelled IHME
0.97 (0.78 - 1.20) 2011 Modelled IHME
0.97 (0.78 - 1.20) 2010 Modelled IHME
0.97 (0.78 - 1.20) 2009 Modelled IHME
0.96 (0.78 - 1.19) 2008 Modelled IHME
0.96 (0.77 - 1.19) 2007 Modelled IHME
0.96 (0.77 - 1.19) 2006 Modelled IHME
0.96 (0.77 - 1.18) 2005 Modelled IHME
0.96 (0.77 - 1.18) 2004 Modelled IHME
0.95 (0.77 - 1.18) 2003 Modelled IHME
0.95 (0.77 - 1.18) 2002 Modelled IHME
0.95 (0.77 - 1.18) 2001 Modelled IHME
0.95 (0.77 - 1.18) 2000 Modelled IHME
0.95 (0.77 - 1.18) 1999 Modelled IHME
0.96 (0.77 - 1.19) 1998 Modelled IHME
0.97 (0.78 - 1.20) 1997 Modelled IHME
0.98 (0.78 - 1.21) 1996 Modelled IHME
0.98 (0.78 - 1.22) 1995 Modelled IHME
0.98 (0.78 - 1.22) 1994 Modelled IHME
0.98 (0.78 - 1.21) 1993 Modelled IHME
0.97 (0.78 - 1.21) 1992 Modelled IHME
0.97 (0.77 - 1.20) 1991 Modelled IHME
0.96 (0.76 - 1.20) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

People who inject drugs (PWID)
Download
Value (%) Year Type Source
34 (27.50 - 41) 2011 Survey/reported Boci A et al, 2013

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
27 (19 - 36) 2019 Modelled IHME
27 (19 - 36) 2018 Modelled IHME
27 (19 - 36) 2017 Modelled IHME
27 (19 - 36) 2016 Modelled IHME
27 (19 - 35) 2015 Modelled IHME
27 (19 - 35) 2014 Modelled IHME
27 (19 - 35) 2013 Modelled IHME
26 (19 - 35) 2012 Modelled IHME
26 (18 - 35) 2011 Modelled IHME
26 (19 - 35) 2010 Modelled IHME
26 (19 - 34) 2009 Modelled IHME
26 (19 - 35) 2008 Modelled IHME
27 (19 - 35) 2007 Modelled IHME
27 (19 - 35) 2006 Modelled IHME
27 (19 - 36) 2005 Modelled IHME
28 (19 - 36) 2004 Modelled IHME
28 (20 - 37) 2003 Modelled IHME
28 (20 - 37) 2002 Modelled IHME
28 (20 - 36) 2001 Modelled IHME
28 (20 - 36) 2000 Modelled IHME
28 (20 - 36) 1999 Modelled IHME
28 (20 - 36) 1998 Modelled IHME
28 (20 - 36) 1997 Modelled IHME
28 (21 - 37) 1996 Modelled IHME
28 (21 - 37) 1995 Modelled IHME
28 (21 - 37) 1994 Modelled IHME
28 (20 - 37) 1993 Modelled IHME
28 (20 - 37) 1992 Modelled IHME
28 (20 - 37) 1991 Modelled IHME
29 (20 - 37) 1990 Modelled IHME
Showing out of
Show more
Technical notes
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes
Year of birth dose introduction
2000
Eligible for HBV generic medicines
HBV National Action Plan
HBV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)

Overview

HBV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.64 (%)
2019
(0.57 - 0.71(%))
IHME
HCV (RNA/cAg+)
1.01 (%)
2019
(0.82 - 1.24(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
123
2019
(83 - 173)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
145
2019
(99 - 201)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.03 (%)
2019, latest modelled
(0.02 - 0.04(%))
IHME

Prevalence PWID

HCV
34 (%)
2011, survey/surveillance
(27.50 - 41(%))
Boci A et al, 2013

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
99 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines